Skip to main content
logo
Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
39.12
-1.34 (-3.31%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Celldex Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-300.55-258.76-157.86-141.43-112.33-70.51
Depreciation & Amortization
3.43.383.183.012.93.07
Loss (Gain) From Sale of Assets
0.010.010.02-0-0.02
Asset Writedown & Restructuring Costs
-----3.5
Loss (Gain) From Sale of Investments
-4.23-5.86-15.75-6.220.84-3.21
Stock-Based Compensation
34.6436.2234.2423.8915.618.95
Other Operating Activities
-----6.86-1.63
Change in Accounts Receivable
-0.14-1.321.93-2.28-0.181.57
Change in Accounts Payable
27.5111.0311.639.383.123.65
Change in Other Net Operating Assets
3.794.34-35.166.36-6.85-6.28
Operating Cash Flow
-235.57-210.95-157.78-107.29-103.73-60.91
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-6.54-2.71-1.92-1.82-1.83-1.25
Sale of Property, Plant & Equipment
----0.070.03
Investment in Securities
-60.59211.79-288.21-103.9691.7-214.93
Investing Cash Flow
-67.13209.07-290.13-105.7889.94-216.16

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
327.112.39441.45218.464.08272.37
Financing Cash Flow
327.112.39441.45218.464.08272.37

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
24.410.52-6.465.39-9.71-4.69

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-242.11-213.66-159.7-109.11-105.56-62.16
Free Cash Flow Growth
------
Free Cash Flow Margin
-153231.01%-13829.06%-2274.89%-1585.19%-4478.57%-1336.44%
Free Cash Flow Per Share
-3.49-3.22-2.48-2.25-2.25-1.45
Levered Free Cash Flow
-133.08-125.54-91.67-46.7-58.03-29.71
Unlevered Free Cash Flow
-133.08-125.54-91.67-46.7-58.03-29.71

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
31.1614.06-21.613.46-3.9-1.05
SEC Filings: 10-K · 10-Q